sitagliptin sold brand name januvia among others antidiabetic medication used treat type united kingdom listed less preferred metformin taken also available fixeddose combination medication sitagliptinmetformin janumet janumet common side effects include headaches swelling legs upper respiratory tract serious side effects may include angioedema low blood sugar kidney problems pancreatitis joint whether use pregnancy breastfeeding safe dipeptidyl inhibitor class works increasing production insulin decreasing production glucagon sitagliptin developed merck co approved medical use united states commonly prescribed medication united states million available generic medication canada united sitagliptin used treat type generally less preferred metformin taken also available fixeddose combinations sitagliptinmetformin janumet janumet sitagliptinsimvastatin sitagliptin used treat type diabetes december us food drug administration fda approved labeling changes stating januvia sitagliptin janumet sitagliptin metformin hydrochloride janumet xr sitagliptin metformin hydrochloride extendedrelease proven improve glycemic blood sugar control children aged type drugs approved improve blood sugar control adults aged older type adverse effects sitagliptin similar placebo except rare nausea common coldlike symptoms increase risk significant difference exists occurrence hypoglycemia placebo taking sulphonylureas risk low blood sugar existence rare case reports kidney failure hypersensitivity reactions noted united states prescribing information causative role sitagliptin several postmarketing reports pancreatitis fatal made people treated sitagliptin us package insert carries warning although causal link sitagliptin pancreatitis yet fully one study lab rats published concluded possible risks pancreatitis pancreatic cancer may reduced used metformin however inhibitors showed increase risk factors increase pancreatic cancer reported individuals taking us food drug administration fda added new warning precaution risk severe disabling joint pain labels inhibitor sitagliptin works competitively inhibit enzyme dipeptidyl peptidase enzyme breaks incretins gip gastrointestinal hormones released response preventing breakdown gip able increase secretion insulin suppress release glucagon alpha cells pancreasmedical citation needed drives blood glucose levels towards normalmedical citation needed blood glucose level approaches normal amounts insulin released glucagon suppressed diminishes thus tending prevent overshoot subsequent low blood sugar hypoglycemia seen oral hypoglycemic agentsmedical citation needed sitagliptin shown lower level points versus placebo slightly less effective metformin used monotherapy cause weight gain less hypoglycemia compared sulfonylureas sitagliptin recommended secondline drug combination drugs combination dietexercise metformin sitagliptin approved us food drug administration fda october marketed us januvia merck co april fda approved oral combination sitagliptinmetformin sold us brand name janumet october fda approved oral combination sitagliptinsimvastatin marketed us httpsenwikipediaorgwikisitagliptin